key: cord-0981437-sx77rysk
authors: Bajrai, Leena Hussein; El-Kafrawy, Sherif Ali; Alnahas, Rabie Saleh; Azhar, Esam Ibraheem
title: In vitro screening of anti-viral and virucidal effects against SARS-CoV-2 by Hypericum perforatum and Echinacea
date: 2021-01-13
journal: bioRxiv
DOI: 10.1101/2021.01.11.426295
sha: 3836f89d323af7ccf577b4386e97da632a76c928
doc_id: 981437
cord_uid: sx77rysk

Special Infectious Agent Unit in King Fahd Medical Research Center at King Abdulaziz University, Jeddah, Saudi Arabia, has pursed the anti-viral project field to optimize the group of medicinal plants for human-infectious diseases. We have begun virtually in this field since COVID-19 pandemic, besides our divergence in the infectious agents’. In this study and based on the previous review, Hypericum perforatum (St. John’s Wort) and Echinacea (gaia HERBS®) were tested in vitro using Vero E6 cells for their anti-viral effects against the newly identified Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) through its infectious cycle from 0 to 48 hours post infection. The hypericin (0.9 mg) of H. perforatum and the different parts (roots, seeds, aerial) of two types of Echinacea species (Echinacea purpurea and Echinacea angustifolia) were examined their efficacy in certain concentration and under light-dependent anti-viral activities to measure the inhibition of the SARS-CoV-2 mRNA expression of RNA-dependent RNA polymerase (RdRP) gene and the viral load with quantitative real-time polymerase chain reaction (qRT-PCR), and to assess the neutralization of the SARS-CoV-2 spike receptor binding on cell culture assay. Interestingly, the mixture (H.E.) of 100 mg/mL of H. perforatum and Echinacea was tested too on SARS-CoV-2 and showed crucial anti-viral activity competing H. perforatum then Echinacea effects as anti-viral treatment. Therefore, the results of gaia HERBS® products, H. perforatum and Echinacea species, applied in this study showed significant anti-viral and virucidal effects in the following order of potency: H. perforatum, H.E., and Echinacea on SARS-CoV-2 infectious cycle; and will definitely required a set up of clinical trial with specific therapeutic protocol based on the outcome of this study. Author Summary After an outbreak of Rift Valley Fever in the Southern region of Saudi Arabia, particularly in May 2003, Special Infectious Agents Unit (SIAU) was established and founded by Prof. Esam Ibraheem Azhar. This unit contains a full range of facilities including Biosafety Level 3, allows him and his research groups to ambulate and culture risk group 3 viruses in Saudi Arabia & Gulf States for the first time. Since that time, SIAU and our international collaboration have been extended to implement a standard protocols in the infectious agents diagnostics procedure through different mode of collaboration including exchange of expertise, joint research program and more recently a technology transfer agreements with number of international institute sharing same interests. Furthermore, we have been engaged in number of researches related to Hajj & Umrah plus number of national services with the Ministry of Health (MOH) through which, we utilize our Mobile biosafety level 3 Lab to enhance the diagnostics of MERS CoV in the Holly sites during Hajj since 2014. In our SIAU and with a powerful team, we have excellent researches made valuable contributions through in vivo and in vitro animal and human studies, and several human viral pathogens which are a threat to global health security due to millions of pilgrims visiting Saudi Arabia every year from 182 countries: with particular areas of interests in: Alkhurma Viral Hemorrhagic Fever, Dengue Hemorrhagic Fever Viruses, Rift Valley Fever Virus, MERS-CoV and more recently the new global infectious diseases threat, Sever Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).

Coronaviruses (CoVs) are a large group of RNA viruses with single-stranded RNA 78 genomes that cause 30% of upper and lower respiratory tract infections in humans. Four main 79 human coronaviruses (HCoVs) are known including severe acute respiratory syndrome 80 SARS-CoV [1], HCoV-NL63 [2] , HCoV-HKU1 [3] , and MERS-CoV in 2012 [4] . CoV-2 originated from Wuhan, Hubei Province of China and spread to the rest of the world 82 causing the global pandemic of COVID-19 with symptoms ranging from cough, fever, and 83 dyspnea to neurological and vascular symptoms [5] . With advancement of the disease, 84 intensive production of pro-inflammatory cytokines findings like: TNF-α, IL-1β, IL-6, IFN-γ, 85 CXCL10, MCP-1, resulting in vasculitis, hyper-coagulability, and multi-organ damage which 86 lead ultimately to death [6] . Main protease (Mpro), known as 3-chymotrypsin-like cysteine 87 protease (3CLpro), has been considered as an important functional target in the viral life 88 cycle, and therefore as a candidate target for anti-viral drugs against SARS-CoV-2 [7, 8] due 89 to its role in the release of functional polypeptides that is encoded by all HCoVs [9, 10] . 90 Updated reports about the disease management from COVID-19 have targeted its structure, 91 pathology, and mechanism in order to have the best solution against the infection by both 92 redesigning and using classical anti-inflammatory agents and by targeting certain cytokine of 93 molecular drug, as per WHO recommendation [11] . For example, numbers of feasible 94 treatment against SARS-CoV-2 were proposed such as: neuraminidase inhibitors, 95 Remdesivir, Peptide (EK1), abidol, RNA synthesis inhibitors (TDF and 3TC), anti-96 inflammatory drugs (hormones and other molecules), and Chinese traditional medicine [12] . 97 Furthermore, there were several studies about the synergy between antimalarial drugs, like 98 Chloroquine-Hydroxychloroquine, Remdesivir-Favipiravir for the treatment of COVID-19 99 [13] [14] [15] . 100 infections especially resulted from E. purpurea root derived a polysaccharide-containing 126 water, and thereby activates phosphatidylinositol-3-kinase (PI3K) of following inhibition of 127 TLR1/2 mediated stimulation of TNF production [39] . Also, alkylamides and ketones of 128 Echinacea extracts reported the anti-inflammatory effects [30, [40] [41] [42] . Another study in 2009 129 against H5N1 HPAIV strain showed that the extract of E. purpurea interferes with the viral 130 entry into cells by blocking the receptor binding activity of the virus [43] . 

The cytotoxicity of H. perforatum, Echinacea and the H.E. mixture of both was 142 evaluated on Vero E6 cell 48h post-treatment using MTT assay. The results showed that most 143 of the plant extracts displayed minimal cytotoxicity at concentrations less than 12.5 µg/mL 144 compared to the cell control ( Figure 1) . Also, the maximum non-toxic concentrations of H. 145 perforatum, Echinacea and H.E. mixture were found to be: 1.56, 6.25, and 6.25 µg/mL; in Table 3 and Figure 2 . 

The black curve represents inhibition of SARS-CoV-2 infection (%) and the red dots represent log concentration 187 (µg/mL) . was Echinacea with 6.25 g/mL concentration. Figure 4 showed the reduction in the viral in the trachea and kidney for chickens infected with IBV, mainly from hypericin content [14] . (Table 2 ). In addition, the mixture effects correlated with reducing the viral 359 load up to 48hrs post infection ( Figure 6 ). trendline that best suited the curve was selected and the correlating equation was used to 447 calculate IC50 values [69] .

The effect of the medicinal plants was tested by the anti-viral assays as following: 450

To determine the effect of H. perforatum, Echinacea and H.E. on SARS CoV-2 infected 452 cells, the Vero E6 cells cultured on 96-well plates were infected with 100 TCID50 of the virus 453 for 2hrs at 37°C, as described previously [14] . Then, treated with 1. 56 at 37°C for 2h [14] . The three extract-treated SARS-CoV-2 were subsequently used to infect 475 Vero E6 cells at 37°C for 48hrs. As described above, the relative mRNA expression levels of , and Virucidal (C) assays; treated and infected cells were included as negative and positive controls (PC), respectively. So, 100 TCID 50 of the virus was added with the certain concentrations of the plant materials when the cells at 80% confluence were complete. The effect of the plant materials was observed clearly with reduction in viral load at 1.56, 6.25, and 6.25 μ g/ml, respectively. The viral load was calculated relatively to virus control wells, and representatives of two independent experiments performed in triplicate are shown. Statistical analysis showed that data were significant with p< 0.005 (one-& two-ways ANOVA). 

Koch's postulates fulfilled for SARS virus

Identification of a new human coronavirus

Detection of the new human 518 coronavirus HKU1: a report of 6 cases

Commentary: Middle 520 east respiratory syndrome coronavirus (mers-cov): announcement of the coronavirus study group

Novel coronavirus COVID-19: an overview for emergency clinicians

main protease provides a basis for design of improved α-ketoamide inhibitors

Origin and evolution of pathogenic coronaviruses

Outbreak of a novel coronavirus

From SARS to SARS-CoV-2, insights on structure, pathogenicity and 532 immunity aspects of pandemic human coronaviruses

The crystal structures of severe acute 535 respiratory syndrome virus main protease and its complex with an inhibitor

Race to find COVID-19 treatments accelerates

Drug treatment options for the 2019-new coronavirus (2019-nCoV)

Infectious Bronchitis Virus and Bioactive Components of Hypericum perforatum L

Clinical use of Hypericum perforatum

depression: a meta-analysis

Characterization of Hypericum perforatum 549 polysaccharides with antioxidant and antimicrobial activities: optimization based statistical 550 modeling

Metabolite profiling and fingerprinting of 552

Hypericum species: a comparison of MS and NMR metabolomics

A 555 REVIEW ON ANTIVIRAL EFFECTS OF NIGELLA SATIVA L

The antiviral agent hypericin has in vitro activity 557 against HSV-1 through non-specific association with viral and cellular membranes

Antimicrobial effect of the extracts from Hypericum 560 perforatum against oral bacteria and biofilm formation

Chemical Composition and 565 antimicrobial activity of the essential oil and methanol extract of Hypericum aegypticum subsp

A review of the antibacterial activity of Hypericum 568 perforatum L

John's wort, against multiresistant Staphylococcus aureus and gram-positive bacteria. The Lancet

Macrophage 573 activation by the polysaccharide arabinogalactan isolated from plant cell cultures of Echinacea 574 purpurea

Macrophage activation and 576 induction of macrophage cytotoxicity by purified polysaccharide fractions from the plant Echinacea 577 purpurea

Alkylamides of Echinacea 579 purpurea stimulate alveolar macrophage function in normal rats

Echinacea alkylamides and ketones are important contributors to the inhibition of prostaglandin E2 583 and nitric oxide production in cultured macrophages

Need for analytical methods and fingerprinting: total quality control of 586 phytomedicine Echinacea

Echinacea alkylamides inhibit 588 interleukin-2 production by Jurkat T cells

Anti-inflammatory and cicatrizing 591 activity of Echinacea pallida Nutt. root extract

Alkylamide and cichoric acid levels in Echinacea purpurea grown in 594

The effect of aerial parts of Echinacea on 596 the circulating white cell levels and selected immune functions of the aging male Sprague-Dawley 597 rat

Echinacea stimulates 599 macrophage function in the lung and spleen of normal rats

Astragalus membranaceus and Glycyrrhiza glabra on CD69 expression and 603 immune cell activation in humans

Natural killer cells from aging mice treated with extracts from Echinacea 605 purpurea are quantitatively and functionally rejuvenated

Echinacea purpurea root extract inhibits TNF 608 release in response to Pam3Csk4 in a phosphatidylinositol-3-kinase dependent manner

Echinacea alkylamides modulate TNF-α gene 611 expression via cannabinoid receptor CB2 and multiple signal transduction pathways

Echinacea and its alkylamides

Effects on the influenza A-induced secretion of cytokines, chemokines, and PGE2 from RAW 264.7 615 macrophage-like cells

Echinacea modulate induced immune responses in macrophages

Anti-viral properties and mode of action of 621 standardized Echinacea purpurea extract against highly pathogenic avian influenza virus

H7N7) and swine-origin H1N1 (S-OIV)

Coronavirus biology and replication: 624 implications for SARS-CoV-2

SARS-CoV-2 626 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Characterization of spike glycoprotein of SARS-CoV-629

on virus entry and its immune cross-reactivity with SARS-CoV

Safety and efficacy 632 of the BNT162b2 mRNA covid-19 vaccine

Identification of antiviral drug candidates 634 against SARS-CoV-2 from FDA-approved drugs

Antiviral effect of diammonium glycyrrhizinate and lithium chloride on cell 637 infection by pseudorabies herpesvirus

Pharmacokinetics, 643 safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic 644 hepatitis C virus infection

St John's wort (Hypericum perforatum L.): a review of 647 its chemistry, pharmacology and clinical properties

Hypericum in 650 infection: Identification of anti-viral and anti-inflammatory constituents

Therapeutic efficacy of Hypericum 653

extract for mice infected with an influenza A virus

Safety and efficacy profile of Echinacea 656 purpurea to prevent common cold episodes: a randomized, double-blind

Evid-Based Complementary Altern Med

Effect of an Echinacea-based hot drink versus 659 oseltamivir in influenza treatment: a randomized, double-blind, double-dummy, multicenter

Efficacy and safety of Echinaforce® in respiratory tract infections

Echinacea reduces the risk of recurrent respiratory tract 664 infections and complications: a meta-analysis of randomized controlled trials

Induction of multiple pro-inflammatory 667

cytokines by respiratory viruses and reversal by standardized Echinacea, a potent antiviral herbal 668 extract

Efficient 670 replication of the novel human betacoronavirus EMC on primary human epithelium highlights its 671 zoonotic potential

The efficacy of Echinacea in a 3-D tissue model of human 673 airway epithelium

In vitro virucidal activity 675 of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses

In vitro 679 testing of hydroxychloroquine and azithromycin on SARS-CoV-2 shows 1 synergistic effect 2. lung

Amotosalen 682 and ultraviolet A light treatment efficiently inactivates severe acute respiratory syndrome 683 coronavirus 2 (SARS-CoV-2) in human plasma

Chemistry, analysis and immunological investigations of Echinacea 685 phytopharmaceuticals. Immunomodulatory agents from plants: Springer

Fatty acid and essential oil composition of Echinacea 687 purpurea (L.) Moench, growing in Kahramanmaras-Turkey. International conference on 688 environmental and biological sciences (ICEBS'2012)

Hyperforin, possibly the major non-nitrogenous secondary metabolite of 690

Biologically active and other chemical constituents of the herb of 692

Evaluation of in-vitro antioxidant and 694 antibacterial properties of Commelina nudiflora L. extracts prepared by different polar solvents

The chemical and 697 antibacterial evaluation of St. John's Wort oil macerates used in Kosovar traditional medicine

In vitro evaluation of the antiviral activity of 700 heparan sulfate mimetic compounds against Enterovirus 71

The strengths of scanning electron microscopy in deciphering SARS-CoV-2 infectious cycle